August 2026
Includes: Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity, picnic and awareness events in July,
New Frontiers: Research Advances for High-Risk and Advanced Prostate Cancer
Beyond imaging and genetic testing, several distinct lines of research reported in 2026 are reshaping how doctors think about high-risk […]
The Genetic Turn: PARP Inhibitors Move Earlier in Prostate Cancer Treatment
One of the most consequential developments in prostate cancer research this year has nothing to do with a new drug […]
Seeing and Striking the Target: How PSMA Is Transforming Prostate Cancer Care
Prostate cancer research in 2026 has been defined by a single molecule: PSMA, or prostate-specific membrane antigen. This protein sits […]
July 2026
Includes: Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity, picnic and awareness events in July,
PARP Inhibitors: Recent Research Advancements in Prostate Cancer (2025–2026)
PARP inhibitors are among the most significant advances in precision medicine for prostate cancer. These drugs work by blocking DNA […]
Two New Approvals, One Clear Direction — Targeted Drug Therapies Come of Age in 2025
The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting […]
“Smart” Radiation Gets Smarter — Lutetium-177 Therapy Expands Its Reach
A treatment once reserved for men who had exhausted nearly every other option is now available earlier in the course […]
A New Standard in Detection — PSMA PET Imaging Is Changing How We Find Prostate Cancer
For decades, diagnosing and staging prostate cancer relied on a combination of CT scans, bone scans, and MRI. That picture […]
June 2026
Includes: Study finds prostate cancer overdiagnosis rises sharply with age, experimental drug shows promise for patients with advanced prostate cancer,